{"id":"trastuzumab-herceptin","brandName":"Trastuzumab (Herceptin)","genericName":"trastuzumab-herceptin","companyId":"pfizer","companyName":"Pfizer Inc.","phase":"marketed","status":"active","modality":"Monoclonal antibody","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":3,"mechanism":{"target":"Receptor tyrosine-protein kinase erbB-2"},"administration":{},"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"indications":{"approved":[{"name":"HER2-positive carcinoma of breast","diseaseId":"her2-positive-carcinoma-of-breast","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"HER2-positive colon cancer","diseaseId":"her2-positive-colon-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"HER2-positive rectal cancer","diseaseId":"her2-positive-rectal-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"HER2-positive salivary gland tumors","diseaseId":"her2-positive-salivary-gland-tumors","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Human epidermal growth factor 2 positive gastric cancer","diseaseId":"human-epidermal-growth-factor-2-positive-gastric-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Secondary malignant neoplasm of female breast","diseaseId":"secondary-malignant-neoplasm-of-female-breast","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Secondary malignant neoplasm of stomach","diseaseId":"secondary-malignant-neoplasm-of-stomach","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":["Advanced Breast Carcinoma","Advanced Colon Carcinoma","Advanced Colorectal Carcinoma","Advanced Endometrial Carcinoma","Advanced Gastric Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Malignant Solid Neoplasm","Advanced Salivary Gland Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","HER2-Positive Breast Carcinoma","Malignant Hepatobiliary Neoplasm","Metastatic Breast Carcinoma","Metastatic Colon Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Endometrial Carcinoma","Metastatic Gastric Carcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Salivary Gland Carcinoma","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Major Salivary Gland Cancer AJCC v8","Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Major Salivary Gland Cancer AJCC v8","Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Unresectable Breast Carcinoma","Unresectable Colon Carcinoma","Unresectable Colorectal Carcinoma","Unresectable Endometrial Carcinoma","Unresectable Gastric Carcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Salivary Gland Carcinoma"],"enrollment":51,"completionDate":"2027-03-31"},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":["Metastatic Malignant Solid Neoplasm","Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":55,"completionDate":"2026-12-31"},{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Locally Advanced Breast Carcinoma","Metastatic Breast Carcinoma","Metastatic HER2-Low Breast Carcinoma","Metastatic HER2-Positive Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Triple-Negative Breast Carcinoma","Unresectable Breast Carcinoma","Unresectable HER2-Low Breast Carcinoma","Unresectable HER2-Positive Breast Carcinoma","Unresectable Hormone Receptor-Positive Breast Carcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Triple-Negative Breast Carcinoma"],"enrollment":36,"completionDate":"2028-01-10"},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":["Breast Cancer","Breast Cancer Female","Breast Cancer, Male","Invasive Breast Cancer","HER2-positive Breast Cancer","HER2 Positive Breast Carcinoma","Stage II Breast Cancer","Stage III Breast Cancer"],"enrollment":31,"completionDate":"2026-07-30"},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":["Metastatic Malignant Solid Neoplasm","Unresectable Malignant Solid Neoplasm"],"enrollment":33,"completionDate":"2027-01-23"},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":720,"completionDate":"2027-01-31"},{"nctId":"NCT07371585","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2026-02-18","conditions":["Breast Cancer Stage IV"],"enrollment":300,"completionDate":"2030-07-01"},{"nctId":"NCT07012031","phase":"PHASE1,PHASE2","title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-07","conditions":["Locally Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8"],"enrollment":37,"completionDate":"2027-06-14"},{"nctId":"NCT04616560","phase":"PHASE2","title":"Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-08","conditions":["Osteosarcoma","Recurrent Osteosarcoma"],"enrollment":77,"completionDate":"2027-12-31"},{"nctId":"NCT07495930","phase":"PHASE1","title":"A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-30","conditions":["Health Adult Subjects"],"enrollment":24,"completionDate":"2026-10-10"},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":["Endometrial Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor"],"enrollment":360,"completionDate":"2027-10-31"},{"nctId":"NCT06178445","phase":"PHASE2","title":"Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2024-04-17","conditions":["Biliary Tract Cancer","HER2 Gene Mutation","HER2"],"enrollment":24,"completionDate":"2027-07"},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":["HER2-positive Breast Cancer"],"enrollment":544,"completionDate":"2029-09"},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":["Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer","Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer"],"enrollment":477,"completionDate":"2027-07-30"},{"nctId":"NCT07195344","phase":"PHASE4","title":"Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2025-10-15","conditions":["Locally Advanced or Metastatic Breast Cancers"],"enrollment":210,"completionDate":"2029-10"},{"nctId":"NCT06136897","phase":"PHASE2","title":"Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-23","conditions":["Malignant Solid Neoplasm"],"enrollment":35,"completionDate":"2027-01-15"},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":["Advanced Lymphoma","Advanced Malignant Solid Neoplasm","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colon Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Esophageal Carcinoma","Exocrine Pancreas Carcinoma","Gastric Carcinoma","Glioma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Kidney Carcinoma","Liver Carcinoma","Lung Carcinoma","Lymphoma","Malignant Uterine Corpus Neoplasm","Malignant Uterine Neoplasm","Melanoma","Multiple Myeloma","Ovarian Carcinoma","Prostate Carcinoma","Rectal Carcinoma","Recurrent Bladder Carcinoma","Recurrent Breast Carcinoma","Recurrent Cervical Carcinoma","Recurrent Colon Carcinoma","Recurrent Colorectal Carcinoma","Recurrent Esophageal Carcinoma","Recurrent Gastric Carcinoma","Recurrent Glioma","Recurrent Head and Neck Carcinoma","Recurrent Liver Carcinoma","Recurrent Lung Carcinoma","Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Malignant Uterine Corpus Neoplasm","Recurrent Melanoma","Recurrent Multiple Myeloma","Recurrent Ovarian Carcinoma","Recurrent Pancreatic Carcinoma","Recurrent Prostate Carcinoma","Recurrent Rectal Carcinoma","Recurrent Skin Carcinoma","Recurrent Thyroid Gland Carcinoma","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Multiple Myeloma","Skin Carcinoma","Thyroid Gland Carcinoma"],"enrollment":6452,"completionDate":"2026-12-31"},{"nctId":"NCT07497386","phase":"PHASE2","title":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":["Unresectable Locally Recurrent Breast Cancer","Unresectable Locally Metastatic Breast Cancer"],"enrollment":150,"completionDate":"2028-12"},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":["Breast Neoplasms"],"enrollment":1000,"completionDate":"2033-07-14"},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":["Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm"],"enrollment":500,"completionDate":"2028-03-31"},{"nctId":"NCT06994377","phase":"","title":"Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-25","conditions":["Metastatic Breast Cancer"],"enrollment":1000,"completionDate":"2029-06"},{"nctId":"NCT07335081","phase":"PHASE2","title":"ctDNA in HER2+ EBC Neoadjuvant Treatment","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-02-01","conditions":["Breast Cancer"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":["Breast Cancer"],"enrollment":2907,"completionDate":"2026-06-30"},{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":["Gastric Neoplasms","Gastroesophageal Adenocarcinoma","Esophageal Adenocarcinoma"],"enrollment":920,"completionDate":"2027-07-31"},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":["Solid Tumor, Adult","Metastatic Breast Cancer","Advanced Breast Cancer","HER2 Mutation-Related Tumors","HER2-positive Metastatic Breast Cancer","KRAS Mutant Metastatic Colorectal Cancer","Metastatic Lung Cancer","Metastatic Colorectal Cancer","Advanced Lung Cancer","HR-positive, HER2-negative Advanced Breast Cancer","HER2-positive Advanced Breast Cancer"],"enrollment":392,"completionDate":"2028-11"},{"nctId":"NCT04639219","phase":"PHASE2","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-30","conditions":["Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast"],"enrollment":102,"completionDate":"2026-07-14"},{"nctId":"NCT04539938","phase":"PHASE2","title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-12-01","conditions":["HER2 Positive Breast Cancer"],"enrollment":70,"completionDate":"2025-03-07"},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8"],"enrollment":2175,"completionDate":"2038-12-31"},{"nctId":"NCT02654119","phase":"PHASE2","title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-12-11","conditions":["HER2 Positive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7"],"enrollment":20,"completionDate":"2025-12-08"},{"nctId":"NCT07015697","phase":"PHASE1","title":"A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-07-17","conditions":["Recurrent or Metastatic Solid Tumors"],"enrollment":76,"completionDate":"2028-12-31"},{"nctId":"NCT05143970","phase":"PHASE1","title":"A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2022-01-21","conditions":["Metastatic Cancer","Metastatic Breast Cancer","Metastatic Pancreatic Cancer","Metastatic Gastric Cancer","Metastatic Lung Cancer","Metastatic Ovary Cancer","Oesophageal Cancer","Endometrial Cancer","Advanced Solid Tumor"],"enrollment":27,"completionDate":"2027-03"},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":["Biliary Tract Cancer"],"enrollment":620,"completionDate":"2029-05-16"},{"nctId":"NCT07294508","phase":"PHASE2,PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":["HER2 + Breast Cancer"],"enrollment":706,"completionDate":"2030-12-30"},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":4200,"completionDate":"2028-12-31"},{"nctId":"NCT05232916","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","status":"RECRUITING","sponsor":"Greenwich LifeSciences, Inc.","startDate":"2022-08-11","conditions":["Breast Cancer"],"enrollment":750,"completionDate":"2026-12"},{"nctId":"NCT05187182","phase":"PHASE1","title":"CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-06-02","conditions":["Gastric Cancer","Esophageal Cancer","Stomach Cancer","Esophagus Cancer","Gastroesophageal Junction Cancer"],"enrollment":42,"completionDate":"2028-06-30"},{"nctId":"NCT06324357","phase":"PHASE1,PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":["Metastatic Breast Cancer","Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Colorectal Cancer"],"enrollment":768,"completionDate":"2029-01-08"},{"nctId":"NCT06973161","phase":"","title":"ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-10","conditions":["Bladder Cancer","Biliary Tract Cancer","Cervical Cancer","Endometrial Cancer","Ovarian Cancer","Pancreatic Cancer","Colorectal Cancer","Lung Cancer","Other Tumors"],"enrollment":105,"completionDate":"2026-04-30"},{"nctId":"NCT05323955","phase":"PHASE2","title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carey Anders, M.D.","startDate":"2023-03-23","conditions":["Brain Metastases","Human Epidermal Growth Factor 2 Positive Carcinoma of Breast","Advanced Breast Cancer"],"enrollment":48,"completionDate":"2026-07"},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":["Advanced Breast Cancer","Metastatic Breast Cancer","Triple Negative Breast Cancer (TNBC)","HER2-negative Breast Cancer","Breast Cancer"],"enrollment":160,"completionDate":"2027-09"},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":726,"completionDate":"2030-02-01"},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":["HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis"],"enrollment":184,"completionDate":"2030-12-30"},{"nctId":"NCT06364410","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-03","conditions":["Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Locally Advanced Gastric Carcinoma","Locally Advanced Gastroesophageal Junction Adenocarcinoma","Locally Advanced Malignant Solid Neoplasm","Metastatic Gastric Carcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Malignant Solid Neoplasm","Unresectable Gastric Carcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":48,"completionDate":"2027-07-08"},{"nctId":"NCT01613482","phase":"PHASE3","title":"TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2008-01","conditions":["Breast Cancer","Metastasis","Sur-expressing Her2-neu"],"enrollment":13,"completionDate":"2012-01"},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":["HER2 Positive Breast Cancer"],"enrollment":654,"completionDate":"2027-09-28"},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":["Colorectal Neoplasms"],"enrollment":400,"completionDate":"2029-07-27"},{"nctId":"NCT07474558","phase":"PHASE2","title":"SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates","status":"NOT_YET_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-09","conditions":["Advanced or Metastatic Solid Tumour","Antibody-Drug Conjugate","Alopecia"],"enrollment":102,"completionDate":"2031-09"},{"nctId":"NCT04253561","phase":"PHASE1","title":"Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2020-02-25","conditions":["Metastatic Breast Cancer"],"enrollment":17,"completionDate":"2025-06-17"},{"nctId":"NCT02858063","phase":"","title":"Psychometric Validation (Quality-of-life Scale) in Young Women With a Non Metastatic Breast Cancer and Her Partner","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2010-01-11","conditions":["Breast Cancer"],"enrollment":1045,"completionDate":"2013-11-27"},{"nctId":"NCT04802759","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":["Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"],"enrollment":316,"completionDate":"2029-05-30"},{"nctId":"NCT03424005","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":["Metastatic Breast Cancer"],"enrollment":792,"completionDate":"2030-09-30"},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":["HER2-positive Breast Cancer"],"enrollment":42,"completionDate":"2029-09-30"},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8"],"enrollment":249,"completionDate":"2027-03-31"},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":["Breast Neoplasms","Breast Cancer","Breast Tumors","Angiosarcoma","TNBC - Triple-Negative Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer"],"enrollment":5000,"completionDate":"2031-12"},{"nctId":"NCT02774421","phase":"PHASE1","title":"Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2017-06-12","conditions":["Posterior Fossa Ependymoma (PFEPN)"],"enrollment":33,"completionDate":"2026-03"},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":["HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients"],"enrollment":55,"completionDate":"2025-12-23"},{"nctId":"NCT06731803","phase":"PHASE1,PHASE2","title":"Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-25","conditions":["Esophagogastric Adenocarcinoma"],"enrollment":36,"completionDate":"2027-12-31"},{"nctId":"NCT04886531","phase":"PHASE2","title":"Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","status":"RECRUITING","sponsor":"Ruth O'Regan","startDate":"2022-07-21","conditions":["Breast Cancer","HER2-positive Breast Cancer","ER Positive Breast Cancer","PR-Positive Breast Cancer"],"enrollment":30,"completionDate":"2027-07"},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":["Endometrial Cancer"],"enrollment":600,"completionDate":"2031-02-19"},{"nctId":"NCT05417594","phase":"PHASE1,PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":["Advanced Solid Malignancies"],"enrollment":695,"completionDate":"2027-08-11"},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":["Colorectal Cancer","Resectable Colorectal Carcinoma"],"enrollment":197,"completionDate":"2028-05"},{"nctId":"NCT07459673","phase":"PHASE2","title":"HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-04","conditions":["Breast Cancer","HER2-positive Breast Cancer","Breast Cancer Stage IV"],"enrollment":60,"completionDate":"2030-03-04"},{"nctId":"NCT05744375","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-09-28","conditions":["Locally Advanced Breast Cancer","Metastatic Breast Cancer"],"enrollment":2,"completionDate":"2025-07-17"},{"nctId":"NCT07102381","phase":"PHASE2","title":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-09-24","conditions":["HER2-positive Breast Cancer","Breast Cancer"],"enrollment":125,"completionDate":"2030-08-01"},{"nctId":"NCT01204372","phase":"PHASE2","title":"Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2010-06","conditions":["Metastatic Pancreatic Adenocarcinoma"],"enrollment":63,"completionDate":"2016-08"},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":["Breast Cancer","Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer"],"enrollment":84,"completionDate":"2031-04-01"},{"nctId":"NCT06057610","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10-16","conditions":["HER2-PositiveRecurrent or Metastatic Breast Cancer"],"enrollment":868,"completionDate":"2032-10"},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":["Breast Cancer","Solid Tumor"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT07465172","phase":"NA","title":"GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Breast Cancer Trials, Australia and New Zealand","startDate":"2026-03","conditions":["Breast Cancer"],"enrollment":150,"completionDate":"2028-09"},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":["Ovarian Cancer"],"enrollment":176,"completionDate":"2028-05-30"},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":["Gastroesophageal Adenocarcinoma"],"enrollment":100,"completionDate":"2028-09-06"},{"nctId":"NCT06048718","phase":"PHASE2","title":"T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2024-06-05","conditions":["Breast Cancer","Metastatic Breast Cancer"],"enrollment":28,"completionDate":"2026-11"},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":["Gastroesophageal Adenocarcinoma"],"enrollment":20,"completionDate":"2027-06"},{"nctId":"NCT07413939","phase":"PHASE2,PHASE3","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":["HER2-positive Breast Cancer"],"enrollment":650,"completionDate":"2032-08-28"},{"nctId":"NCT04285671","phase":"PHASE1,PHASE2","title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-01-29","conditions":["Metastatic Lung Non-Small Cell Carcinoma","Refractory Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":30,"completionDate":"2027-12-02"},{"nctId":"NCT04829604","phase":"PHASE2","title":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ambrx, Inc.","startDate":"2021-10-26","conditions":["HER2 Positive Metastatic Breast Cancer"],"enrollment":72,"completionDate":"2027-06"},{"nctId":"NCT06764875","phase":"PHASE3","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-01","conditions":["HER2-positive Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"enrollment":840,"completionDate":"2030-12-09"},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":["Solid Tumors"],"enrollment":920,"completionDate":"2032-09-25"},{"nctId":"NCT07454668","phase":"PHASE1","title":"Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-06","conditions":["Breast Cancer","HER2-positive Breast Cancer","Brain Metastases","Cancer","Cancer Metastatic"],"enrollment":20,"completionDate":"2029-07"},{"nctId":"NCT06819007","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-19","conditions":["Ovarian Cancer"],"enrollment":582,"completionDate":"2032-01-31"},{"nctId":"NCT05672524","phase":"PHASE2","title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-12-30","conditions":["Adenocarcinoma of the Rectum","Locally Advanced Rectal Adenocarcinoma","Rectal Adenocarcinoma","HER2 Positive Rectal Adenocarcinoma","Rectal Cancer"],"enrollment":37,"completionDate":"2030-07-31"},{"nctId":"NCT02675829","phase":"PHASE2","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-02","conditions":["Solid Tumor Cancers","Lung Cancer","Bladder Cancer","Urinary Tract Cancers"],"enrollment":131,"completionDate":"2027-02"},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":866,"completionDate":"2026-06-19"},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":["Breast Cancer"],"enrollment":1188,"completionDate":"2034-10-02"},{"nctId":"NCT07214766","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-17","conditions":["Healthy Participants"],"enrollment":312,"completionDate":"2026-04-15"},{"nctId":"NCT07446452","phase":"PHASE2","title":"Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":["HER2-low Breast Cancer"],"enrollment":37,"completionDate":"2027-01-01"},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":["Advanced Breast Cancer","Advanced Breast Carcinoma","Hormone Receptor Positive Breast Carcinoma"],"enrollment":200,"completionDate":"2028-01"},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":["Resectable HER2-positive Breast Cancer"],"enrollment":1800,"completionDate":"2035-08-07"},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":["HER2-positive Breast Cancer"],"enrollment":53,"completionDate":"2027-09"},{"nctId":"NCT05573893","phase":"","title":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-12","conditions":["Breast Neoplasms","Breast Cancer","Neoplasm Metastasis"],"enrollment":800,"completionDate":"2031-12-31"},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":["Metastatic Breast Cancer","HER2-positive Breast Cancer"],"enrollment":162,"completionDate":"2029-09-17"},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":["Dynamic Tumor Resistance","Metastatic Colorectal Cancer"],"enrollment":100,"completionDate":"2029-11-14"},{"nctId":"NCT07436858","phase":"PHASE1","title":"Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-08-01","conditions":["Lung Cancer (NSCLC)","HER2 Expression","HER2 Gene Mutation"],"enrollment":20,"completionDate":"2030-06-01"},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":["Breast Cancer","HER2-positive Breast Cancer","Early Breast Cancer"],"enrollment":186,"completionDate":"2028-12-30"},{"nctId":"NCT06750484","phase":"PHASE2","title":"Trial of Trastuzumab Deruxtecan in Previously Treated HER2","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-06-20","conditions":["Breast Cancer Metastatic"],"enrollment":40,"completionDate":"2028-12-31"},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":["Gastroesophageal-junction Cancer","Monoclonal Antibody","Gastric Cancer","HER2-positive Gastric Cancer"],"enrollment":550,"completionDate":"2028-09-01"},{"nctId":"NCT04294628","phase":"PHASE1","title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":["Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Unresectable Malignant Solid Neoplasm"],"enrollment":62,"completionDate":"2027-01-19"},{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":["Breast Cancer"],"enrollment":608,"completionDate":"2025-12-23"},{"nctId":"NCT03448042","phase":"PHASE1","title":"A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2018-06-06","conditions":["Solid Tumors"],"enrollment":123,"completionDate":"2026-11-30"},{"nctId":"NCT05593094","phase":"PHASE1,PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":["Advanced Solid Tumors","HER2-positive Breast Cancer"],"enrollment":210,"completionDate":"2027-07-31"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=trastuzumab-herceptin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:47:38.334461+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:47:44.753813+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=trastuzumab-herceptin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:47:45.546604+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:47:46.112551+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201585/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:47:46.020787+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:47:47.884514+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1201585"},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}